Robert Mass - MEI Pharma Chief Medical Officer
| MEIP Stock | USD 2.43 0.03 1.22% |
Executive
Dr. Robert D. Mass, M.D., is Chief Medical Officer of the MEI Pharma, Inc. Dr. Mass has more than 20 years of experience as a medical oncologist in both clinical practice and clinical drug development. He held a number of leadership positions at Genentech from 1998 to 2009, most recently as Head of Medical Affairs, BioOncology, a position created to strategically integrate and optimize all of the nonsponsored clinical programs within the companys oncology portfolio. He also served on the Executive Development Review Committee at Genentech, which was responsible for the review and approval of all sponsored clinical programs across the companys therapeutic portfolio. Previously he served as clinical science leader for Herceptin from 1999 to 2002, Tarceva from 2002 to 2003, and Avastin, currently the leading oncology therapeutic worldwide, from 2003 to 2007. Prior to joining Genentech, he practiced Hematology and Medical Oncology from 1988 to 1998. After leaving Genentech, Dr. Mass served as a consultant for several oncology companies, including MEI Pharma from October 2010 until his appointment as Chief Medical officer in June 2011. Dr. Mass consulted for Stem CentRx, Inc., a privately held biotechnology company, on a parttime basis, as its acting Chief Medical Officer until his resignation on December 31, 2014 since 2011.
| Age | 71 |
| Tenure | 14 years |
| Address | 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121 |
| Phone | 858 369 7100 |
| Web | https://meipharma.com |
MEI Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3068) % which means that it has lost $0.3068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9368) %, meaning that it created substantial loss on money invested by shareholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/05/2025, Return On Tangible Assets is likely to grow to 0.41. Also, Return On Capital Employed is likely to grow to 0.42. At this time, MEI Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 03/05/2025, Non Current Liabilities Other is likely to grow to about 26.8 M, while Total Current Liabilities is likely to drop slightly above 8.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Theresa Lowry | Zura Bio Limited | 51 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| MD FACC | ZyVersa Therapeutics | 75 | |
| Thomas Rollins | Assembly Biosciences | 69 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Amy CFA | Assembly Biosciences | N/A | |
| PharmD Mordwinkin | Kezar Life Sciences | 43 | |
| Gary Whale | Zura Bio Limited | 50 | |
| Donald Notman | Ocular Therapeutix | 57 | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Philip Esq | Ocular Therapeutix | 64 | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| Andrew Gengos | Terns Pharmaceuticals | 61 | |
| James Kanter | Terns Pharmaceuticals | N/A | |
| Beatrix StelteLudwig | Vincerx Pharma | N/A | |
| Zung To | Kezar Life Sciences | N/A | |
| Gitanjali Jain | Kezar Life Sciences | N/A | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
Management Performance
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.31 |
MEI Pharma Leadership Team
Elected by the shareholders, the MEI Pharma's board of directors comprises two types of representatives: MEI Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MEI. The board's role is to monitor MEI Pharma's management team and ensure that shareholders' interests are well served. MEI Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MEI Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Justin CPA, CFO CEO | ||
| BA Esq, COO Counsel | ||
| Anne Frese, Chief Officer | ||
| Eugene Park, VP Marketing | ||
| Virginia Sankey, VP Fin | ||
| JD Esq, Chief Officer | ||
| Eric Deng, VP Operations | ||
| Richard Ghalie, Chief Officer | ||
| MBA MD, Chief Officer | ||
| LLM JD, Senior Affairs | ||
| Robert Mass, Chief Medical Officer | ||
| BA CPA, CFO Sec | ||
| Justin File, CFO Secretary | ||
| Nicole Iida, Vice Affairs | ||
| Daniel Gold, CEO and President and Director | ||
| Yomara GomezNaiden, Senior Quality |
MEI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MEI Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (21.95 M) | ||||
| Shares Outstanding | 6.66 M | ||||
| Shares Owned By Insiders | 1.31 % | ||||
| Shares Owned By Institutions | 40.60 % | ||||
| Number Of Shares Shorted | 4.18 K | ||||
| Price To Earning | 30.29 X | ||||
| Price To Book | 0.74 X | ||||
| Price To Sales | 0.27 X |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.